236 related articles for article (PubMed ID: 27257215)
1. Jmjd2/Kdm4 demethylases are required for expression of Il3ra and survival of acute myeloid leukemia cells.
Agger K; Miyagi S; Pedersen MT; Kooistra SM; Johansen JV; Helin K
Genes Dev; 2016 Jun; 30(11):1278-88. PubMed ID: 27257215
[TBL] [Abstract][Full Text] [Related]
2. Continual removal of H3K9 promoter methylation by Jmjd2 demethylases is vital for ESC self-renewal and early development.
Pedersen MT; Kooistra SM; Radzisheuskaya A; Laugesen A; Johansen JV; Hayward DG; Nilsson J; Agger K; Helin K
EMBO J; 2016 Jul; 35(14):1550-64. PubMed ID: 27266524
[TBL] [Abstract][Full Text] [Related]
3. The KDM4/JMJD2 histone demethylases are required for hematopoietic stem cell maintenance.
Agger K; Nishimura K; Miyagi S; Messling JE; Rasmussen KD; Helin K
Blood; 2019 Oct; 134(14):1154-1158. PubMed ID: 31434704
[TBL] [Abstract][Full Text] [Related]
4. KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells.
Berry WL; Janknecht R
Cancer Res; 2013 May; 73(10):2936-42. PubMed ID: 23644528
[TBL] [Abstract][Full Text] [Related]
5. JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors.
Chen M; Zhu N; Liu X; Laurent B; Tang Z; Eng R; Shi Y; Armstrong SA; Roeder RG
Genes Dev; 2015 Oct; 29(20):2123-39. PubMed ID: 26494788
[TBL] [Abstract][Full Text] [Related]
6. KDM6 and KDM4 histone lysine demethylases emerge as molecular therapeutic targets in human acute myeloid leukemia.
Boila LD; Chatterjee SS; Banerjee D; Sengupta A
Exp Hematol; 2018 Feb; 58():44-51.e7. PubMed ID: 29111428
[TBL] [Abstract][Full Text] [Related]
7. KDM4 inhibitor SD49-7 attenuates leukemia stem cell
Li Y; Wang C; Gao H; Gu J; Zhang Y; Zhang Y; Xie M; Cheng X; Yang M; Zhang W; Li Y; He M; Xu H; Zhang H; Ji Q; Ma T; Ding S; Zhao Y; Gao Y
Theranostics; 2022; 12(11):4922-4934. PubMed ID: 35836814
[No Abstract] [Full Text] [Related]
8. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337
[TBL] [Abstract][Full Text] [Related]
9. KDM4 Demethylases: Structure, Function, and Inhibitors.
Jiang Y; Liu L; Yang ZQ
Adv Exp Med Biol; 2023; 1433():87-111. PubMed ID: 37751137
[TBL] [Abstract][Full Text] [Related]
10. The oncogenic potential of Jumonji D2 (JMJD2/KDM4) histone demethylase overexpression.
Young LC; Hendzel MJ
Biochem Cell Biol; 2013 Dec; 91(6):369-77. PubMed ID: 24219278
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Potentials of Inhibition of Jumonji C Domain-containing Demethylases in Acute Myeloid Leukemia.
Koca D; Hastar N; Engür S; Kiraz Y; Ulu GT; Çekdemir D; Baran Y
Turk J Haematol; 2020 Feb; 37(1):5-12. PubMed ID: 31833715
[TBL] [Abstract][Full Text] [Related]
12. CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.
Bonifant CL; Szoor A; Torres D; Joseph N; Velasquez MP; Iwahori K; Gaikwad A; Nguyen P; Arber C; Song XT; Redell M; Gottschalk S
Mol Ther; 2016 Sep; 24(9):1615-26. PubMed ID: 27401038
[TBL] [Abstract][Full Text] [Related]
13. KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.
Chin YW; Han SY
Expert Opin Ther Pat; 2015 Feb; 25(2):135-44. PubMed ID: 25468267
[TBL] [Abstract][Full Text] [Related]
14. Advances in histone demethylase KDM4 as cancer therapeutic targets.
Lee DH; Kim GW; Jeon YH; Yoo J; Lee SW; Kwon SH
FASEB J; 2020 Mar; 34(3):3461-3484. PubMed ID: 31961018
[TBL] [Abstract][Full Text] [Related]
15. Heme promotes transcriptional and demethylase activities of Gis1, a member of the histone demethylase JMJD2/KDM4 family.
Lal S; Comer JM; Konduri PC; Shah A; Wang T; Lewis A; Shoffner G; Guo F; Zhang L
Nucleic Acids Res; 2018 Jan; 46(1):215-228. PubMed ID: 29126261
[TBL] [Abstract][Full Text] [Related]
16. Comparative integromics on JMJD2A, JMJD2B and JMJD2C: preferential expression of JMJD2C in undifferentiated ES cells.
Katoh Y; Katoh M
Int J Mol Med; 2007 Aug; 20(2):269-73. PubMed ID: 17611647
[TBL] [Abstract][Full Text] [Related]
17. Critical role of Jumonji domain of JMJD1C in MLL-rearranged leukemia.
Izaguirre-Carbonell J; Christiansen L; Burns R; Schmitz J; Li C; Mokry RL; Bluemn T; Zheng Y; Shen J; Carlson KS; Rao S; Wang D; Zhu N
Blood Adv; 2019 May; 3(9):1499-1511. PubMed ID: 31076406
[TBL] [Abstract][Full Text] [Related]
18. KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB-Regulated Genes.
Duan L; Rai G; Roggero C; Zhang QJ; Wei Q; Ma SH; Zhou Y; Santoyo J; Martinez ED; Xiao G; Raj GV; Jadhav A; Simeonov A; Maloney DJ; Rizo J; Hsieh JT; Liu ZP
Chem Biol; 2015 Sep; 22(9):1185-96. PubMed ID: 26364928
[TBL] [Abstract][Full Text] [Related]
19. Structural and evolutionary basis for the dual substrate selectivity of human KDM4 histone demethylase family.
Hillringhaus L; Yue WW; Rose NR; Ng SS; Gileadi C; Loenarz C; Bello SH; Bray JE; Schofield CJ; Oppermann U
J Biol Chem; 2011 Dec; 286(48):41616-41625. PubMed ID: 21914792
[TBL] [Abstract][Full Text] [Related]
20. Histone demethylase JMJD2B/KDM4B regulates transcriptional program via distinctive epigenetic targets and protein interactors for the maintenance of trophoblast stem cells.
Mak KH; Lam YM; Ng RK
Sci Rep; 2021 Jan; 11(1):884. PubMed ID: 33441614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
